

Silvia Darb-Esfahani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1681075/publications.pdf>

Version: 2024-02-01

45
papers

4,654
citations

236925

25
h-index

233421

45
g-index

45
all docs

45
docs citations

45
times ranked

9192
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 713-720.	2.5	7
2	Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging. <i>Cancers</i> , 2021, 13, 1512.	3.7	14
3	EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. <i>Molecular Cancer Research</i> , 2020, 18, 278-286.	3.4	12
4	Stable expansion of high-grade serous ovarian cancer organoids requires a low Wnt environment. <i>EMBO Journal</i> , 2020, 39, e104013.	7.8	70
5	PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy. <i>Cancer Research and Treatment</i> , 2020, 52, 689-696.	3.0	29
6	MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1700181.	1.6	45
7	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2018, 20, 280-288.	5.3	23
8	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. <i>Clinical Cancer Research</i> , 2018, 24, 3358-3365.	7.0	11
9	Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years. <i>Modern Pathology</i> , 2018, 31, 607-615.	5.5	25
10	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. <i>Lancet Oncology</i> , The, 2018, 19, 40-50.	10.7	1,327
11	Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2018, 119, 1060-1066.	6.4	47
12	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. <i>British Journal of Cancer</i> , 2018, 119, 330-338.	6.4	13
13	Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival. <i>Histopathology</i> , 2018, 73, 1002-1012.	2.9	12
14	The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2018, 150, 151-157.	1.4	21
15	Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor ± in high-grade serous ovarian carcinoma. <i>Human Pathology</i> , 2017, 67, 30-36.	2.0	11
16	Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 143-151.	2.8	2
17	Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. <i>British Journal of Cancer</i> , 2017, 116, 1287-1293.	6.4	22
18	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7621-7632.	7.0	31

#	ARTICLE	IF	CITATIONS
19	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 758-766.	2.8	21
20	High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. <i>Oncotarget</i> , 2017, 8, 102912-102922.	1.8	57
21	Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration. <i>Journal of Cancer</i> , 2016, 7, 546-554.	2.5	42
22	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) associations with gene expression, mutational load, and survival. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 626-639.	2.8	80
23	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2675-2683.	7.0	41
24	Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. <i>European Journal of Cancer</i> , 2016, 53, 51-64.	2.8	45
25	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBC 69): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 345-356.	10.7	316
26	Wilms tumor protein 1 (WT1) Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 140, 494-502.	1.4	26
27	Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. <i>Cancer Research</i> , 2016, 76, 796-804.	0.9	74
28	Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. <i>Oncotarget</i> , 2016, 7, 67686-67698.	1.8	50
29	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. <i>Oncotarget</i> , 2016, 7, 1486-1499.	1.8	212
30	Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC). <i>Journal of Clinical Oncology</i> , 2015, 33, 5534-5534.	1.6	3
31	PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. <i>Anticancer Research</i> , 2015, 35, 6329-34.	1.1	13
32	Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 16-22.	1.4	20
33	Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. <i>BMC Cancer</i> , 2014, 14, 546.	2.6	68
34	Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1681-1689.	2.5	13
35	Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization. <i>PLoS ONE</i> , 2012, 7, e51862.	2.5	983
36	Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. <i>Histopathology</i> , 2011, 59, 918-927.	2.9	21

#	ARTICLE	IF	CITATIONS
37	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 477-487.	2.5	180
38	mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2011, 18, 181-192.	3.1	90
39	Prognostic significance of Dicer expression in ovarian cancer—link to global microRNA changes and oestrogen receptor expression. <i>Journal of Pathology</i> , 2010, 220, 382-391.	4.5	84
40	Effect of neoadjuvant anthracycline—taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 133-140.	2.5	252
41	Expression of classical NF- κ B pathway effectors in human ovarian carcinoma. <i>Histopathology</i> , 2010, 56, 727-739.	2.9	30
42	Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. <i>Endocrine-Related Cancer</i> , 2009, 16, 1229-1239.	3.1	31
43	Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 455, 461-467.	2.8	11
44	Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 933-941.	2.5	74
45	Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. <i>Breast Cancer Research</i> , 2009, 11, R69.	5.0	95